Biathlon

Biathlon is a sport with documented doping cases, with 43 registered cases (0.3% of all violations). Russian Federation leads in violations with 22 cases, while Erythropoietin is the most frequently detected substance (13 cases). The average suspension length is 30.4 months. Biathlon ranks #37 globally among all sports tracked by the Anti-Doping Database..

Number of cases in Biathlon Last 10 Years

International Biathlon Union

Homepage:

Contact:
[email protected]

If you use this statistics, please credit The Anti-Doping Database

Sport Global Ranking
1,493
···
43
Global Ranking: #37 of 178 sports

43

Biathlon cases

0.3%

Of all violations

14,670

Total global cases
Biathlon's share of all violations 0.3%
43 of 14,670

Biathlon has the most violations in anti-doping rule violations globally, with 43 registered cases0.3% of all 14,670 verified cases in the Anti-Doping Database. Based on verified cases in the Anti-Doping Database.

Number of cases in Biathlon By Country
Top Country: Russian Federation

22

Russian Federation cases

51.2%

Of global cases

43

Total Biathlon cases
Russian Federation's share of Biathlon violations 51.2%
22 of 43

Russian Federation dominates Biathlon with 22 registered violations, accounting for over 51.2% of all violations. This represents 51.2% of the sport's 43 total cases globally.

The average suspension length for sanctioned Biathlon athletes in Russian Federation is 30.4 months, aligned with the global average.

Substance use in Biathlon
Most Detected Substance: Erythropoietin

13

Biathlon cases

30.2%

Of sport cases

598

Global Erythropoietin cases
Erythropoietin's share of Biathlon violations 30.2%
13 of 43

Erythropoietin leads significantly in Biathlon with 13 violations out of 43 total cases (30.2%). Representing more than one-third of all violations.

Globally, Erythropoietin has been detected in 598 cases across all sports, ranking #6 among all prohibited substances.

The average suspension length for Erythropoietin violations is 39.4 months, longer than the global average of 30.1 months.


What is Erythropoietin (EPO)?

Erythropoietin (EPO) is a naturally occurring hormone that stimulates red blood cell production. Synthetic EPO became available as a pharmaceutical drug in the late 1980s, primarily for medical use in patients with anemia and kidney disease. Related drugs, such as Darbepoetin Alfa, have since been developed.

Why Athletes Use It

In sports, EPO enhances oxygen-carrying capacity by increasing red blood cell count, providing significant advantages in endurance events such as cycling, long-distance running, and cross-country skiing. The increased oxygen delivery to muscles can dramatically improve stamina and performance.

Health Risks

Artificially elevated red blood cell levels thicken the blood, significantly increasing the risk of serious cardiovascular complications including blood clots, heart attack, stroke, hypertension, seizures, and congestive heart failure. The risks are particularly acute during sleep when heart rate naturally decreases, as the thickened blood becomes more difficult to circulate at lower heart rates.

Prohibition and Testing

EPO was added to the IOC prohibited list in 1989, initially categorized under peptide hormones and analogues. However, testing methods were not immediately available, allowing widespread use in the early 1990s.

On August 1, 2000, the IOC Medical Commission approved two detection methods for EPO based on isoelectric focusing and double immunoblotting, which distinguish between natural and synthetic EPO in urine samples. Modern detection methods and hematocrit monitoring have made EPO use more detectable, though related substances and microdosing practices continue to challenge anti-doping authorities.

Notable Cases and Controversies

Belgian cycling champion Eddy Planckaert later confessed to experimenting with EPO in 1991, his final professional year, stating that many riders were using the substance during that period. Several Dutch and Belgian cyclists died suddenly in the late 1980s and early 1990s, sparking widespread concern about EPO's dangers.

However, academic research has questioned whether EPO was the cause of these deaths. A 2011 study by sports historian Bernat López examined claims that 18 Dutch and Belgian cyclists died from EPO use between 1987-1990 and found the claim lacked empirical evidence. López noted that reported numbers varied wildly across sources (from 6 to 40 deaths) and that most sudden deaths in young athletes are attributed to underlying cardiac conditions rather than drug use. The study concluded that the "18 deaths" narrative functioned more as anti-doping propaganda than historical fact.

Sources


If you use this statistics, please credit The Anti-Doping Database

Number of Active Sanctions Ending Year for Biathlon
Gender Distribution
Male 48.8
21 cases
Female 51.2
22 cases
Analysis: Biathlon shows an unusually high proportion of female cases (51.2%) compared to the global average (19.8%), a difference of 31.4 percentage points. Global average: 80.2% male, 19.8% female

About International Biathlon Union

The intelligence tool for anti-doping professionals

Used by journalists, sport lawyers, NADOs and researchers worldwide for proactive strategy — not just post-case research.

 

As a subscriber you get instant access to verified, structured anti-doping case data — from hours of research to seconds:

  • Complete athlete and sanction details
    • Identity, ban periods, substances used, test type, violation information and more.
  • Verified documents and case materials
    • Access sanction decisions, PDFs and official sources when available.
  • Advanced insights and historical trends
    • Statistics across sports, countries, substances and year-by-year comparisons — for proactive planning, not just post-case analysis.

The Anti-Doping Database currently contains 14,670 verified anti-doping rule violations across all sports and all countries, and is updated regularly.